Yahoo News Search
CM AND Product Data Management overlap
Philips Forms alliance with CellPoint
Researchers Discover Unusual Protein Structure
Threat to movement of research samples lifted
Bayer’s acceptance of disease targets is a first for proteomics
Player follows partner directly targeting the highly regulated pharma segment.
Frost & Sullivan analyses the emerging European injectable drug delivery market
A Comment By Eric E. Gay, Analyst Drug Discovery & Proteomics, Frost & Sullivan
Documentum targets pharma
Nobex’ drug delivery technology replaces injections with pills
Findings Published in Peer Reviewed Journal Nature Biotechnology
One Million Cell Assays With the Living Chip Technology
Life sciences industry bucks trend
Patents being infringed, says company
Survey shows down market
Combinational chemistry constitutes a powerful tool for drug discovery and development.
XML tools provider finds logistics support
‘No compelling scientific arguments that GM crops are innately different from non-GM crops" says UK ‘s John Innes Centre
Bio trade organisation EuropaBio gives its verdict
An endorsement for Crucell’s unique vaccine ‘tool box’
Americans get more new drugs than any other country
Company gets FDA clearance for 90 patient Phase II clinical trial for brain cancer treatment 2 April 2002
One company's divestment could be another company's perfect fit 25 March 2002
There are conflicting financial indicators from the healthcare sector but two conferences in the US and UK could help investors sort it out 20 March 2002
A compound that appears to kill the malaria parasite would make more donations safe for the global blood bank 15 March 2002
Many genetic disorders, such as cystic fibrosis, are directly related to membrane proteins, but fewer than 30 such structures are presently known
Factors driving this growth include rapid acceptance of new biology methods
Two companies have joined together to be a single source provider of genomics resources in drug discovery 7 March 2002
A newly available bioengineered human skin is a step away from needing to use live animals in pharmaceutical research 5 March 2002
2001 was a very good year for biotech M&A, and says Ernst & Young, 2002 is also looking good. 15 February 2002
Give your story premium visibility!
Communicado deals
